Marielle E Yohe
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marielle E Yohe as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07891286 · Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young AdultsNational Cancer Institute (NCI) · not yet recruiting · LGCMN, Large and Giant Congenital Melanocytic Nevi, NF1 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advancing RAS and RASopathy TherapiesZIABC011869 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $849,996 awarded in 2025Same name and institution; not confirmed by an ID
- Improving Pediatric Melanoma Outcomes in a Longitudinally Evaluated CohortZIABC012175 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $607,140 awarded in 2025Same name and institution; not confirmed by an ID
- Regulation of differentiation and invasion in RMS by ASAP1ZIABC011993 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2025 · $121,429 awarded in 2025Same name and institution; not confirmed by an ID
- Targeting RAS in Pediatric CancerZIABC011892 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2019 to 2025 · $607,140 awarded in 2025Same name and institution; not confirmed by an ID
- The role of SMARCA1 in Rhabdomyosarcoma and Skeletal Muscle DifferentiationZIABC012148 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 to 2025 · $242,856 awarded in 2025Same name and institution; not confirmed by an ID
- Dual Blockade of IGF1R and MEK synergistically inhibits pediatric cancersZIABC011804 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2024 · $516,915 awarded in 2024Same name and institution; not confirmed by an ID
- Defining the Mechanism of Action of Rigosertib in Pediatric CancersZIABC011805 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2018 to 2021 · $222,334 awarded in 2021Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in ependymoma.